Are you a community physician treating patients with multiple myeloma?
If so, this workshop is for you!
Because of the limited experience with T cell redirection treatment strategies in the real world and especially bispecific T cell engagers and CAR T therapies among oncologists and health care professionals outside CAR T administering centers, there is a gap in the understanding, management and utilization of these therapies in patients that might benefit from these types of treatments. As more drug products become available through commercial and research routes, there will be a greater need for a close partnership between the centers where these treatments are administered and the smaller community centers where the vast majority of oncology patients are typically followed and receive the bulk of their treatments. There is an urgent need to bridge this knowledge gap and raise awareness of novel immune based strategies including antibody drug conjugates, bispecific T cell engagers and CAR T therapies among health care professionals.
Mark your calendars for the 23rd IMS Annual Meeting in Glasgow, Scotland.
The International Myeloma Society Meeting is the defining annual meeting in myeloma with a focus on both the basic, preclinical, and clinical aspects. This year’s program includes:
Four thematic sessions:
Newly Diagnosed Multiple Myeloma
How to Treat First Relapse
Blood-Based Technology for Diagnosis and Monitoring
Monitoring Immune System and Preventing Infections and Adverse Effects
Talks and symposia led by key opinion leaders in the myeloma community
Keynote addresses
Joint sessions with regulatory agencies and other organizations
This high-impact educational program, held in conjunction with the DGHO Annual Meeting, seeks to bridge the knowledge gap between CAR T administering centers and smaller community centers where the vast majority of oncology patients are treated, and raise awareness of novel immune based strategies including antibody drug conjugates, bispecific T cell engages, and CAR T therapies among healthcare professionals.
Not attending the DGHO Annual Meeting? Select the “On-demand Registration” option to receive access to the recording approximately 3 weeks post-meeting.
For information about corporate support opportunities:
Sue Deveaux
Sr. Vice President, Healthcare Events and Expositions
SPARGO, Inc.
703-995-3866 Sue.deveaux@spargoinc.com
Why Become a Member
The International Myeloma Society is a professional, scientific, and medical society established to bring together clinical and experimental scientists involved in the study of myeloma. The purpose of this society is to promote research, education, clinical studies (including diagnosis and treatment), workshops, conferences, and symposia on all aspects of multiple myeloma worldwide.
The IMS is a membership organization comprised of basic research scientists, and clinical investigators in the field along with physicians and other healthcare practitioners.
